Nurix Therapeutics (NRIX) Stock Price & Analysis

NRIX$15.48-0.12 -0.77%
BiotechnologyValue StockGrowth StockHigh Quality
Compare
Market cap$1.69BEnterprise value$2.22BRevenue (TTM)$701.94MMarket position—

Score

85
Bullish
Value
69
Quality
97
Growth
90

AI Analysis

Snapshot

Nurix Therapeutics mixes growth with a still-reasonable multiple — Growth 90/100 with P/E 10.5. Under the hood: P/E 10.5, plus revenue compounding ~41% annually over recent years. Street targets still imply ~130% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

69
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

90
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

97
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Nurix Therapeutics, Inc. (NRIX) last printed $15.48. Equity value is $1.69B. Trailing earnings multiple 5.86. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20182019202020212022202320242025
$37.45M$31.11M$17.82M$29.75M$38.63M$76.99M$54.55M$83.98M

About

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Nurix Therapeutics (NRIX) Stock Price & Analysis

NRIX price $15.48 -0.12 -0.77%

Ticker
NRIX
Price
$15.48
Change
-0.12 -0.77%
Market cap
$1.69B
P/E
5.86
Forward P/E
11.21
Dividend yield
0.00%
Beta
1.80
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
85
Value
69
Quality
97
Growth
90

Stocklytics score rationale: value 69, quality 97, growth 90.

Fair value

NRIX fair value $66.87. Price $15.48. Price is 77% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value is the earnings value from next-twelve-months EPS times 28.4, a blend of the industry median and the stock's own 10-year median. A cash-flow value is not available for this stock. How we calculate it →

Model uncertainty high for this stock

Compare NRIX

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-02-17—-0.42—37.97M
2027-01-27—-0.46—287.86M
2026-10-124.73-0.60673.06M24.35M
2026-07-09-0.81-0.729.04M15.29M
2026-04-08-0.79-0.766.25M14.25M
2026-01-28-0.82-0.8413.58M13.40M
2025-10-09-1.03-0.847.89M12.26M
2025-07-09-0.52-0.7144.06M17.51M
2025-04-08-0.67-0.7218.45M15.82M
2025-01-28-0.75-0.6713.28M14.78M
2024-10-11-0.67-0.6712.59M12.81M
2024-07-11-0.71-0.6612.09M22.10M
2024-04-10-0.76-0.8016.59M17.30M
2024-02-15-0.77-0.5115.16M22.26M
2023-10-12-0.68-0.6918.47M15.98M
2023-07-13-0.45-0.6330.68M26.21M
2023-04-13-0.75-0.9012.69M10.87M
2023-02-09-0.87-0.686.78M17.17M
2022-10-06-0.90-0.9910.79M12.07M
2022-07-07-1.01-1.0011.43M10.51M
2022-04-07-0.95-0.899.62M9.27M
2022-01-27-0.85-0.677.40M13.19M
2021-10-14-0.65-0.6310.25M10.41M
2021-07-13-0.60-0.547.09M8.23M
2021-04-13-0.63-0.465.01M4.74M
2021-02-16-0.51-0.546.69M—
2020-10-14-0.59-0.414.08M3.78M
2020-07-24-0.60—2.86M—
2020-05-310.22—4.18M—
2019-11-30-0.65—1.86M—
2019-08-31-0.12—10.58M—
2019-05-31-0.94—9.44M—
2019-02-28-0.85—9.23M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-11-04van Houte HansSell3.30K$15.3850.76K
2026-11-04van Houte HansSell1.47K$16.2023.80K
2026-11-03Ring ChristineSell6.11K$25.83157.92K
2026-11-02Ring ChristineSell5.79K$8.7250.45K
2026-11-02Ring ChristineBuy5.79K$8.7250.45K
2026-11-02Ring ChristineSell9.53K$25.74245.22K
2026-11-02Ring ChristineSell1.07K$26.7628.77K
2026-11-02Hansen GwennBuy1.45K$1.862.70K
2026-11-02Hansen GwennSell1.45K$26.8038.91K
2026-11-02Hansen GwennSell1.45K$1.862.70K
2026-10-30van Houte HansBuy3.57K——
2026-10-30van Houte HansSell2.83K$26.2874.47K
2026-10-30van Houte HansBuy2.86K——
2026-10-30van Houte HansBuy3.75K——
2026-10-30van Houte HansSell3.57K——
2026-10-30van Houte HansSell2.86K——
2026-10-30van Houte HansSell3.75K——
2026-10-30Ring ChristineSell3.57K——
2026-10-30Ring ChristineBuy3.57K——
2026-10-30Ring ChristineSell2.86K——
2026-10-30Ring ChristineBuy2.86K——
2026-10-30Ring ChristineSell3.96K$26.28103.99K
2026-10-30Ring ChristineBuy3.75K——
2026-10-30Ring ChristineSell3.75K——
2026-10-30Hansen GwennBuy3.57K——
2026-10-30Hansen GwennBuy2.86K——
2026-10-30Hansen GwennSell3.96K$26.28103.99K
2026-10-30Hansen GwennBuy3.75K——
2026-10-30Hansen GwennSell3.57K——
2026-10-30Hansen GwennSell2.86K——
2026-10-30Hansen GwennSell3.75K——
2026-10-15Hansen GwennBuy1.45K$1.862.70K
2026-10-15Hansen GwennSell1.45K$25.0036.30K
2026-10-15Hansen GwennSell1.45K$1.862.70K
2026-10-14GREGORY JULIA PBuy22.58K$1.8642.00K
2026-10-14GREGORY JULIA PSell22.58K$23.40528.53K
2026-10-14GREGORY JULIA PSell22.58K$1.8642.00K
2026-10-02Ring ChristineSell5.79K$8.7250.45K
2026-10-02Ring ChristineBuy5.79K$8.7250.45K
2026-10-02Ring ChristineSell5.79K$23.19134.15K
2026-09-02Ring ChristineSell5.79K$8.7250.46K
2026-09-02Ring ChristineBuy5.79K$8.7250.46K
2026-09-02Ring ChristineSell5.39K$25.69138.42K
2026-09-02Ring ChristineSell400$26.6410.65K
2026-09-01Hansen GwennBuy1.45K$1.862.70K
2026-09-01Hansen GwennSell1.45K$25.4736.98K
2026-09-01Hansen GwennSell1.45K$1.862.70K
2026-08-05Hansen GwennBuy4.36K$1.868.10K
2026-08-05Hansen GwennSell4.36K$25.00108.90K
2026-08-05Hansen GwennSell4.36K$1.868.10K
2026-08-04Hansen GwennSell1.50K$23.8735.80K
2026-08-04Hansen GwennSell2.61K$24.6464.34K
2026-08-04van Houte HansSell1.79K$23.8942.86K
2026-08-04van Houte HansSell2.97K$24.6573.13K
2026-08-03Ring ChristineSell5.79K$8.7250.46K
2026-08-03Ring ChristineBuy5.79K$8.7250.46K
2026-08-03Ring ChristineSell16.59K$23.05382.36K
2026-07-30van Houte HansBuy3.57K——
2026-07-30van Houte HansSell2.85K$23.3866.52K
2026-07-30van Houte HansBuy2.86K——
2026-07-30van Houte HansBuy3.75K——
2026-07-30van Houte HansSell3.57K——
2026-07-30van Houte HansSell2.86K——
2026-07-30van Houte HansSell3.75K——
2026-07-30Ring ChristineSell3.57K——
2026-07-30Ring ChristineBuy3.57K——
2026-07-30Ring ChristineBuy2.86K——
2026-07-30Ring ChristineSell2.86K——
2026-07-30Ring ChristineSell3.85K$23.3889.95K
2026-07-30Ring ChristineBuy3.75K——
2026-07-30Ring ChristineSell3.75K——
2026-07-30Hansen GwennBuy3.57K——
2026-07-30Hansen GwennBuy2.86K——
2026-07-30Hansen GwennSell3.85K$23.3889.95K
2026-07-30Hansen GwennBuy3.75K——
2026-07-30Hansen GwennSell3.57K——
2026-07-30Hansen GwennSell2.86K——
2026-07-30Hansen GwennSell3.75K——
2026-07-02Ring ChristineSell5.79K$8.7250.46K
2026-07-02Ring ChristineBuy5.79K$8.7250.46K
2026-07-02Ring ChristineBuy5.22K$1.869.71K
2026-07-02Ring ChristineSell11.01K$23.56259.37K
2026-07-02Ring ChristineSell5.22K$1.869.71K
2026-06-25Hansen GwennSell5.39K$20.00107.88K
2026-06-25Ring ChristineSell15.60K$8.72136.05K
2026-06-25Ring ChristineBuy15.60K$8.72136.05K
2026-06-25Ring ChristineBuy13.33K$7.2696.80K
2026-06-25Ring ChristineSell28.93K$20.06580.51K
2026-06-25Ring ChristineSell13.33K$7.2696.80K
2026-06-02Ring ChristineBuy3.42K$1.866.36K
2026-06-02Ring ChristineSell8.15K$16.60135.25K
2026-06-02Ring ChristineSell3.42K$1.866.36K
2026-05-15Silva Paul MBuy31.25K$15.86495.62K
2026-05-15Saltzman Edward CBuy31.25K$15.86495.62K
2026-05-15Reinsdorf Judith ABuy31.25K$15.86495.62K
2026-05-15Lacey David L.Buy31.25K$15.86495.62K
2026-05-15Kapur AnilBuy31.25K$15.86495.62K
2026-05-15DANSEY ROGER DBuy31.25K$15.86495.62K
2026-05-15Baynes Roy D.Buy31.25K$15.86495.62K
2026-05-15GREGORY JULIA PBuy31.25K$15.86495.62K

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 158, holders -60 vs prior quarter. Ownership 54.69%.

HolderSharesChangeChange %Value
BLACKROCK, INC.8.80M30.89K+0.35%208.68M
MORGAN STANLEY5.25M484.03K+10.16%124.39M
FMR LLC4.68M-805.40K-14.68%110.96M
VANGUARD CAPITAL MANAGEMENT LLC4.50M9.24K+0.21%106.81M
STATE STREET CORP4.43M-248.57K-5.31%105.00M
GENERAL ATLANTIC, L.P.3.03M00.00%71.89M
GEODE CAPITAL MANAGEMENT, LLC2.52M-21.42K-0.84%59.66M
ARK INVESTMENT MANAGEMENT LLC1.85M59.39K+3.31%43.92M
CAPITAL WORLD INVESTORS1.79M00.00%42.39M
DIMENSIONAL FUND ADVISORS LP1.31M-116.38K-8.13%31.18M
EVENTIDE ASSET MANAGEMENT, LLC1.30M00.00%30.77M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1.28M803.56K+168.41%30.37M
VANGUARD PORTFOLIO MANAGEMENT LLC1.26M-221.36K-14.93%29.91M
PICTET ASSET MANAGEMENT HOLDING SA1.13M-1.22M-51.92%26.80M
AFFINITY ASSET ADVISORS, LLC967.62K00.00%22.94M
MARSHALL WACE, LLP872.76K872.76KNew20.69M
NUVEEN, LLC865.95K40.12K+4.86%20.53M
SUMITOMO MITSUI TRUST GROUP, INC.863.08K-120.39K-12.24%20.46M
AMOVA ASSET MANAGEMENT AMERICAS, INC.863.08K-120.39K-12.24%20.44M
KENNEDY CAPITAL MANAGEMENT LLC753.47K28.96K+4.00%17.86M
HANDELSBANKEN FONDER AB750.00K117.00K+18.48%17.78M
LORD, ABBETT & CO. LLC729.42K729.42KNew17.30M
UBS GROUP AG690.56K-226.55K-24.70%16.37M
VANGUARD FIDUCIARY TRUST CO687.26K924+0.13%16.29M
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A.641.53K641.53KNew15.21M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener